ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Clinical and MRI features associated with amyloid positivity in secondary screening for anti-amyloid-β therapy.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn Japan, confirmatory biomarker testing for Alzheimer's disease (AD) is insurance-covered only when evaluating eligibility for anti-amyloid-β therapies. This study aimed to identify clinical and magnetic resonance imaging (MRI) features associated with amyloid positivity in a real-world setting.
methodsWe reviewed patients attending our secondary screening clinic between 2023 and 2024. After clinical discussions, interested patients underwent 3T MRI and either amyloid positron emission tomography (PET) or cerebrospinal fluid biomarker testing.
resultsOf the 200 patients, 147 proceeded to evaluation and 138 had biomarker results. The amyloid-positive group ( DISCUSSION: Younger age and lower MMSE scores were associated with amyloid positivity. Caution regarding referral bias for early-onset AD in real-world settings is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.